Do topical antiglaucoma drugs affect the cornea?

Güneş, İrfan Botan; Öztürk, Hakan; Özen, Bediz

doi:10.1177/11206721211016981

Cited by 4 publications

(19 citation statements)

References 46 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, effects of AGV implantation were comparable to effects of MTMT on ECD changes and graft survival in patients with penetrating keratoplasty for at least 12 months. However, surprisingly, the reduction in ECD with MTMT of PKP eyes for bullous keratopathy was greater than those eyes with normal ECD in previous studies ( 5 , 7 , 16 ). This is the first report to evaluate ECD changes with MTMT in corneal transplanted eyes so far.…”

Section: Discussioncontrasting

confidence: 69%

“…Evidence suggests that the topical anti-glaucoma medication is not directly involved in the reduction of ECD in patients with glaucoma patients (7) or corneal donor grafts (8). However, the long-term use of topical anti-glaucoma medication induces significant ocular surface changes in patients who underwent PKP, such as dry eye, superficial punctate keratitis, conjunctival scarring, and ocular surface inflammation (9)(10)(11)(12)(13), which may affect not only the success of subsequent glaucoma surgery but also graft survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Outcomes in Maximum Tolerated Medical Therapy in Penetrating Keratoplasty for Bullous Keratopathy

Kim

Jeoung

et al. 2022

Front. Med.

View full text Add to dashboard Cite

PurposeTo compare the clinical outcomes of maximum tolerated medical therapy (MTMT) in patients with penetrating keratoplasty (PKP) with those of Ahmed glaucoma valve (AGV) implantation.MethodsThe medical records were retrospectively reviewed in patients who had undergone PKP for bullous keratopathy and were treated with MTMT or AGV implantation for the management of glaucoma. A total of 18 bullous keratopathic patients were investigated between January 2010 and February 2017: 9 patients treated with MTMT and 9 patients treated with AGV implantation. Non-corrected visual acuity (NCVA), intraocular pressure (IOP), endothelial cell density (ECD), hexagonality, coefficient of variation (CV), central corneal thickness (CCT), median survival time of the graft, and the presence of epithelial keratopathy were compared between the groups at each time point or between baseline and after treatment of glaucoma in each group.ResultsThere were no significant differences in the visual acuity and corneal thickness between the two groups or within each group over time. Both groups showed a significant reduction in IOP compared with the baseline IOP, and IOP reductions were greater in the AGV group than in the MTMT group (p = 0.040). Significant ECD reductions were found in each group between the baseline and 6 months (p = 0.008 in the MTMT group, p = 0.015 in the AGV group); however, no differences were found between the two groups until 12 months. The significant hexagonality reduction was found in the AGV group between the baseline and 12 months (p = 0.018). The median survival time showed no significant difference in the survival analysis.ConclusionsMaximum tolerated medical therapy in penetrating keratoplasty for bullous keratopathy seems to similarly affect the endothelial cell density or graft survival when compared with at least 12 month-followed Ahmed glaucoma valve implantation.

show abstract

Section: Discussioncontrasting

confidence: 69%

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes in Maximum Tolerated Medical Therapy in Penetrating Keratoplasty for Bullous Keratopathy

Kim

Jeoung

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Therefore, it is speculated that continued use of PGA eyedrops induces desensitization of PG F receptors and slows the increase in MMP [31]. Second, Liu et al suggested that PGA eye drops, especially Latanoprost, could induce corneal fibroblast contraction in an in vitro study and affect corneal thickness reduction [32,33]. Finally, Shen et al reported that Latanoprost might have a cytotoxic effect on corneal stromal cells, inducing apoptosis and thus reducing corneal thickness [32,34].…”

Section: Discussionmentioning

confidence: 99%

“…Second, Liu et al suggested that PGA eye drops, especially Latanoprost, could induce corneal fibroblast contraction in an in vitro study and affect corneal thickness reduction [32,33]. Finally, Shen et al reported that Latanoprost might have a cytotoxic effect on corneal stromal cells, inducing apoptosis and thus reducing corneal thickness [32,34]. The proposed mechanism for CCT increase during PGA eyedrop use is as follows.…”

Section: Discussionmentioning

confidence: 99%

Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review

Kim

Yim

2022

JCM

View full text Add to dashboard Cite

To investigate whether prostaglandin analogue (PGA) eyedrops have a significant effect on central corneal thickness (CCT), we conducted a systematic search of literature published from 2000 to 2021. Among the studies conducted on topical PGA therapy in open-angle glaucoma or ocular hypertension patients over 18 years old, prospective studies with CCT change as an outcome were included. A single-arm meta-analysis was conducted to assess the overall effect on CCT, and subgroup analysis according to exposure time of PGA eyedrops was also performed. We counted the number of articles that reported on severe events (CCT reduction of 25 μm or more) and obtained their proportion. The methodological quality was assessed by the McHarm tool. Twenty-two reports of prospective studies were selected. The results of the single-arm meta-analysis showed very high heterogeneity. Still, in subgroup analysis, when PGA was used for more than 6 months, heterogeneity was low, and a significant decrease in CCT was observed. Severe events were reported in two reports and occurred in 3.8% to 14.8% of participants. PGA eyedrop use may cause a clinically significant CCT decrease, requiring CCT follow-up.

show abstract

“…Apart from the intended activation of MMPs in targeted ocular tissues, non-targeted tissues such as cornea undergo upregulation of MMPs [ 69 ]. Since cornea is rich in collagen, studies have shown that use of PGAs causes lowering of central corneal thickness (CCT) [ 11 , 40 , 69 – 71 ].…”

Section: Methodology Of Literature Searchmentioning

confidence: 99%

The Multifarious Effects of Various Glaucoma Pharmacotherapy on Corneal Endothelium: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Corneal endothelium is a single cell layer that is mainly responsible for maintaining corneal clarity. Endothelial damage secondary to toxicity, stress, or genetic predisposition are common and in conjunction with the low regenerative ability of the cells, making their preservation critical for maintaining visual acuity. Patients with glaucoma, who are estimated to be close to 80 million worldwide, have a plethora of reasons for developing endothelial damage, being exposed to a spectrum that extends from various medical and surgical interventions to the disease itself. The wide spectrum of glaucoma pharmacotherapy that has been recently extended by addition of newer classes of medications has been the focus of extensive research on its effects on corneal endothelium. Both basic and clinical research have attempted to shine a light on the complex mechanisms associated with the effects of glaucoma medication on corneal endothelium and to answer the important question as to whether these findings are clinically significant. The aim of this review is to summarize and present current literature of the various findings, both from in vivo and in vitro studies that have focused on the complex relationship between different classes of glaucoma medication and their effect on corneal endothelium.

show abstract

Do topical antiglaucoma drugs affect the cornea?

Cited by 4 publications

References 46 publications

Clinical Outcomes in Maximum Tolerated Medical Therapy in Penetrating Keratoplasty for Bullous Keratopathy

Clinical Outcomes in Maximum Tolerated Medical Therapy in Penetrating Keratoplasty for Bullous Keratopathy

Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review

The Multifarious Effects of Various Glaucoma Pharmacotherapy on Corneal Endothelium: A Narrative Review

Contact Info

Product

Resources

About